ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Applications of circulating tumor DNA in unresectable and advanced non-small cell lung cancer immunotherapy: from stratification to therapeutic guidance.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related mortality worldwide. Although immune checkpoint inhibitors (ICIs) have significantly improved outcomes in patients with unresectable stage III and advanced disease, the lack of robust predictive biomarkers continues to limit patient selection and treatment optimization. Circulating tumor DNA (ctDNA) has emerged as a minimally invasive and dynamic biomarker that enables comprehensive tumor profiling. In this review, we summarize recent advances in ctDNA detection technologies, including quantitative PCR, digital PCR, and next-generation sequencing approaches, and discuss their clinical applications in immunotherapy. We highlight the role of ctDNA in pre-treatment stratification to identify patients most likely to benefit, as well as its utility in real-time monitoring of therapeutic response and disease progression. Furthermore, we discuss emerging high-sensitivity techniques and multi-omics integration strategies that may further enhance the precision of ctDNA-based analysis. Overall, ctDNA holds significant potential to refine clinical decision-making and advance personalized immunotherapy in unresectable and advanced NSCLC.
Indexed as
Identifiers
42803873What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.